RxDoctor Payments DataLook up a doctor →

Michael Esposito, MD

Interventional Pain Medicine · Vero Beach, FLNPI 1043521198

Payments from drug & device makers

$1,015,510in general payments, 2019–2025

Across 1,590 payments — averaging $638.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$568K
  • Orthofundamentals, LLC$172K
  • Abbott$126K
  • Nevro Corp.$41K
  • Medtronic$30K
  • Vertiflex, Inc.$29K
  • plus $49K from 44 others

What the payments were for

  • Consulting fees$189,24224%
  • Speaking & faculty fees$475,47461%
  • Travel & lodging$65,7388%
  • Food & beverage$45,6246%
  • Education$3210%
  • Entertainment$1770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,015,510 in reported general payments places this provider in the 95th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,258,247
Medicare patients
867
Services billed
19,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate70$38,522
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,137$37,158
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,314$35,872
LyricaPregabalin19$23,960
Pregabalin662$20,848
Gabapentin852$16,956
MovantikNaloxegol Oxalate47$16,063
OxycontinOxycodone Hcl23$15,839
Duloxetine Hcl448$11,058
Buprenorphine26$8,960
Diclofenac Sodium320$7,565
Tramadol Hcl643$6,460
Fentanyl59$6,405
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$5,072
Oxycodone Hcl228$4,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$188$38,52270 claims
PfizerLyrica$31$23,96019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →